Lipoxin A4

Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA) -mediated IL-8 release with an IC50 value of 25.74 nM[3].

Product Specifications

CAS Number

[89663-86-5]

Product Name Alternative

LXA4

UNSPSC

12352211

Hazard Statement

H225, H319

Target

Endogenous Metabolite; Interleukin Related

Type

Natural Products

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lipoxin-a4.html

Concentration

283.71 μM * 250 μL in Ethanol

Purity

98.00

Solubility

10 mM in DMSO

Smiles

CCCCC[C@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](O)CCCC(O)=O

Molecular Formula

C20H32O5

Molecular Weight

352.47

Precautions

H225, H319

References & Citations

[1]Feng Hu, et al. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF-κB pathways. J Dermatol Sci. 2015 Jun;78 (3) :181-8.|[2]Steven Bozinovski, et al. Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012 Jan 17;109 (3) :935-40.|[3]Xinxin Liu, et al. Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis.Sci Rep. 2017 Aug 2;7 (1) :7100.|[4]Miao GS, et al. Lipoxin A4 attenuates radicular pain possibly by inhibiting spinal ERK, JNK and NF-κB/p65 and cytokine signals, but not p38, in a rat model of non-compressive lumbar disc herniation. Neuroscience. 2015 Aug 6;300:10-8.